1 citations,
August 2013 in “Journal of the National Cancer Institute” Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.
21 citations,
March 2013 in “Cancer Epidemiology, Biomarkers & Prevention” Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.
11 citations,
April 2013 in “Journal of Agricultural and Food Chemistry” Monascus helps prevent baldness, prostate issues, and may be a natural alternative to medications.
6 citations,
January 2016 in “Evidence-based complementary and alternative medicine” Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
28 citations,
June 2010 in “European Journal of Cancer” Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.
December 2023 in “International Journal of Molecular Sciences” Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.
52 citations,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
April 2012 in “The Journal of Urology” PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
12 citations,
October 2018 in “Aging male/The aging male” Higher BMI and lower testosterone are linked to more aggressive prostate cancer.
6 citations,
February 2013 in “Medical Oncology” Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
9 citations,
July 2018 in “Medicine” Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.
25 citations,
December 2008 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
113 citations,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
148 citations,
April 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
24 citations,
February 2012 in “Prostate cancer and prostatic diseases” 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
4 citations,
April 2020 in “Reports of Practical Oncology & Radiotherapy” Prostate cancer patients need early psychological and sexual support during radiotherapy to improve their quality of life.
3 citations,
December 2014 in “Journal of Clinical Oncology” Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.
9 citations,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
February 2012 in “Expert Review of Endocrinology & Metabolism” The document suggests more research is needed to understand the link between baldness and prostate cancer.
218 citations,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
1 citations,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
Finasteride is popular for treating male hair loss but may increase the risk of serious prostate cancer and has other potential side effects.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.